GenomOncology’s platform provides the capability to identify cohorts of patients within the institution eligible for clinical trials and novel therapies. Credit: ibbl.

University Hospitals Seidman Cancer Center in the US has selected GenomOncology’s Precision Decision and GO Connect solutions to streamline the matching of patients to the increasing number of clinical trials and therapies.

The platform will help University Hospitals to help scale its precision oncology programme and streamlines a complicated process to assist patients and doctors.

University Hospitals selected the new platform as it needed access to all curated biomarker-based and institutional non-biomarker clinical trials.

GenomOncology’s platform also provides the capability to identify cohorts of patients within the institution eligible for clinical trials and novel therapies.

Additionally, it allows University Hospitals to conduct feasibility analysis to launch new clinical trials across all of its locations wholly-owned by Seidman Cancer Center.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University Hospitals Seidman Cancer Center president and scientific director Dr Theodoros Teknos said: “Due to the speed and complexity of genetic and biomarker discoveries, it is virtually impossible for any oncologist to remain current on all the clinical trials and newly approved cancer therapies.

“Through this partnership with GenomOncology, we have leveraged the power of computing to process incredible amounts of data and identify the optimal care for every patient.”

University Hospitals will use GenomOncology’s Precision Decision and GO Connect solutions to efficiently match patients to therapies, as well as relevant, open clinical trials.

The solution will also be used to ingest data from the institutions’ clinical data warehouse and clinical trial matching system and transform it into usable information available within GenomOncology’s Precision Decision product.

University Hospitals will also be able to identify and interact with all therapies and curated clinical trials in a single dashboard, through which users can search for eligible patients at their institution.

The University Hospitals team can also examine their internal database of clinical and molecular profiles of patients to determine the feasibility of opening new clinical trials.